Beta Bionics (NASDAQ:BBNX) Stock: Insider Mark Hopman Sells 821 Shares

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 821 shares of Beta Bionics stock in a transaction on Monday, October 26th. The shares were sold at an average price of $20.00, for a total transaction of $16,420.00. Following the completion of the transaction, the insider owned 54,513 shares in the company, valued at approximately $1,090,260. This represents a 1.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Mark Hopman also recently made the following trade(s):

• On Wednesday, October 14th, Mark Hopman sold 775 shares of Beta Bionics stock. The stock was sold at an average price of $17.35, for a total transaction of $13,446.25.
• On Thursday, October 1st, Mark Hopman sold 370 shares of Beta Bionics stock. The stock was sold at an average price of $18.96, for a total value of $7,015.20.
• On Wednesday, September 16th, Mark Hopman sold 30,779 shares of Beta Bionics stock. The shares were sold at an average price of $20.13, for a total value of $619,581.27.
• On Wednesday, September 9th, Mark Hopman sold 36,870 shares of Beta Bionics stock. The stock was sold at an average price of $18.46, for a total transaction of $680,620.20.
• On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The shares were sold at an average price of $19.11, for a total transaction of $101,798.97.

Beta Bionics Price Performance

BBNX opened at $17.58 on Friday. Beta Bionics, Inc. has a 1 year low of $8.80 and a 1 year high of $32.71. The firm has a 50 day moving average price of $19.16 and a 200 day moving average price of $14.89.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings results on Tuesday, October 27th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.01. The firm had revenue of $35.51 million for the quarter. Beta Bionics had a negative return on equity of 27.33% and a negative net margin of 65.31%. As a group, analysts forecast that Beta Bionics, Inc. will post -2.02 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Beta Bionics

A number of institutional investors have recently modified their holdings of the stock. Perceptive Advisors LLC raised its stake in shares of Beta Bionics by 39.8% during the 1st quarter. Perceptive Advisors LLC now owns 842,944 shares of the company’s stock worth $8,446,000 after purchasing an additional 240,000 shares in the last quarter. BlackRock Inc. acquired a new stake in shares of Beta Bionics during the 2nd quarter valued at about $52,340,000. Bank of New York Mellon Corp bought a new stake in shares of Beta Bionics in the 2nd quarter valued at approximately $1,926,000. Squarepoint Ops LLC bought a new stake in shares of Beta Bionics in the 2nd quarter valued at approximately $2,524,000. Finally, Bruce & Co. Inc. bought a new stake in shares of Beta Bionics in the 1st quarter valued at approximately $5,518,000.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on BBNX. Weiss Ratings upgraded Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 18th. TD Cowen increased their price target on Beta Bionics from $18.00 to $21.00 and gave the company a “hold” rating in a research report on Wednesday. Barclays initiated coverage on Beta Bionics in a research note on Tuesday, October 6th. They issued an “overweight” rating and a $30.00 price target on the stock. Piper Sandler restated an “overweight” rating and set a $24.00 price objective (up from $20.00) on shares of Beta Bionics in a report on Wednesday. Finally, Truist Financial upped their price objective on shares of Beta Bionics from $23.00 to $28.00 and gave the company a “buy” rating in a research note on Thursday, September 24th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $23.69.

Key Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Third-quarter results slightly exceeded expectations. Beta Bionics reported a loss of $0.52 per share versus the consensus estimate of a $0.53 loss, while revenue of $35.51 million topped analyst expectations of roughly $34.7 million. The company also updated its 2026 guidance, though details were not provided in the available reports. Beta Bionics third-quarter results
• Positive Sentiment: Analyst support remains favorable. Stifel Nicolaus maintained its Buy rating, while other analysts have raised price targets. The consensus rating remains Moderate Buy, with an average target price of $23.69, above the recent trading level.
• Neutral Sentiment: Insider selling was relatively limited in the latest filings. Director Mark Hopman sold 821 shares for approximately $16,420, reducing his ownership by about 1.48%. Another insider, Mike Mensinger, sold 2,650 shares for $58,300. The transactions may weigh on sentiment, but represent small portions of their remaining holdings. SEC insider filing
• Negative Sentiment: Multiple law firms publicized a pending securities class action. The lawsuit covers investors who purchased BBNX shares between July 30, 2025, and February 24, 2026. Investors have until November 3, 2026, to seek lead-plaintiff status. The repeated notices increase legal and reputational risks for Beta Bionics.
• Negative Sentiment: The allegations focus on FDA and iLet safety disclosures. Legal notices allege that the company’s filings did not fully disclose issues tied to an FDA warning and hundreds of potentially serious iLet complaints, including alleged life-threatening hypoglycemia incidents. These claims have not been proven, but possible regulatory action, litigation costs, or additional product concerns could pressure the stock. Beta Bionics securities class action notice
• Negative Sentiment: Execution risk remains an additional concern. The company has disclosed risks related to the commercial launch of its next-generation Mint patch pump, potentially clouding its growth outlook.

About Beta Bionics

Beta Bionics, Inc (NASDAQ: BBNX) is a medical technology company focused on developing and commercializing automated insulin-delivery systems for people with insulin-dependent diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with limited user input.

The iLet Bionic Pancreas combines a wearable insulin pump with continuous glucose monitoring technology and adaptive dosing algorithms. The system is designed to automatically adjust insulin delivery based on an individual’s glucose readings and requires users to provide relatively simple meal announcements rather than calculate precise carbohydrate amounts.